J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals

08 Jul 2024
pmlive.com
Clinical ResultDrug ApprovalPhase 3Phase 2
J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals
Preview
Source: PMLiVE
Johnson & Johnson (J&J) has received approvals from both the European Commission (EC) and US Food and Drug Administration (FDA) for its tuberculosis (TB) treatment, Sirturo (bedaquiline).
The EC has granted the drug full approval to treat pulmonary multidrug-resistant tuberculosis (MDR-TB) as part of an appropriate combination regimen in adult and paediatric patients aged five years and older and weighing at least 15kg.
The EU regulator’s decision, which specifically indicates Sirturo when other combinations cannot be used because the disease is resistant to them or because of their side effects, follows a recent recommendation from the European Medicines Agency’s human medicines committee and converts its previous 2014 conditional approval of the drug to a standard marketing authorisation.
The FDA has also granted Sirturo traditional approval for use as part of a combination therapy for adult and paediatric patients, also aged five years and older and weighing at least 15kg, with pulmonary MDR-TB. The approval removes the label restrictions that were included when the medicine was granted accelerated approval in the US in 2012, J&J outlined.
The new authorisations were based on results from the phase 3 STREAM stage 2 study, in which a Sirturo-containing regimen offered a significant improvement in treatment outcomes for patients with MDR-TB compared to injectable-containing regimens.
An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022, according to the World Health Organization, which also noted that the treatment success rate for patients diagnosed with this form of the infection remains “alarmingly low” despite improvements.
The decisions on Sirturo come just days after J&J’s Rybrevant (amivantamab) was approved by the EC as a first-line treatment for non-small cell lung cancer (NSCLC).
The bispecific antibody was specifically authorised for use alongside carboplatin and pemetrexed chemotherapy to treat advanced NSCLC in adults with epidermal growth factor receptor exon 20 insertion mutations.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.